Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules
Nassima Oumata, Kui Lu, Yuou Teng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114578-114578
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 111
Exploring novel derivatives of isatin-based Schiff bases as multi-target agents: design, synthesis,in vitrobiological evaluation, andin silicoADMET analysis with molecular modeling simulations
Ashraf S. Hassan, Nesrin M. Morsy, Wael M. Aboulthana, et al.
RSC Advances (2023) Vol. 13, Iss. 14, pp. 9281-9303
Open Access | Times Cited: 55
In-depth investigation of the mechanisms of Schisandra chinensis polysaccharide mitigating Alzheimer's disease rat via gut microbiota and feces metabolomics
Jun Fu, Jixun Li, Yuzhen Sun, et al.
International Journal of Biological Macromolecules (2023) Vol. 232, pp. 123488-123488
Closed Access | Times Cited: 53
In vitro enzymatic evaluation of some pyrazolo[1,5‐a]pyrimidine derivatives: Design, synthesis, antioxidant, anti‐diabetic, anti‐Alzheimer, and anti‐arthritic activities with molecular modeling simulation
Ashraf S. Hassan, Nesrin M. Morsy, Wael M. Aboulthana, et al.
Drug Development Research (2022) Vol. 84, Iss. 1, pp. 3-24
Closed Access | Times Cited: 61
Preclinical Models for Alzheimer’s Disease: Past, Present, and Future Approaches
Ansab Akhtar, Shraddha Manish Gupta, Shubham Dwivedi, et al.
ACS Omega (2022) Vol. 7, Iss. 51, pp. 47504-47517
Open Access | Times Cited: 41
Development of promising acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, in vitro and in silico approaches of pyridine derived fused bis-oxadiazole and bis-thiadiazole derivatives
Rafaqat Hussain, Shoaib Khan, Yousaf Khan, et al.
Journal of Molecular Structure (2024) Vol. 1310, pp. 138228-138228
Closed Access | Times Cited: 9
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jiang, Ji Li, Xiaohui Yao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Kaempferol as a potential neuroprotector in Alzheimer's disease
Hamid Reza Nejabati, Leila Roshangar
Journal of Food Biochemistry (2022) Vol. 46, Iss. 12
Open Access | Times Cited: 23
Carbamate as a potential anti‐Alzheimer's pharmacophore: A review
Yash Pal Singh, Navneet Kumar, Brijesh Singh Chauhan, et al.
Drug Development Research (2023) Vol. 84, Iss. 8, pp. 1624-1651
Closed Access | Times Cited: 14
Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1,3,4-oxadiazol-2-yl)thio) as Multifunctional Agents to Combat Alzheimer’s Disease
Digambar Kumar Waiker, Akash Verma, Poorvi Saraf, et al.
ACS Omega (2023) Vol. 8, Iss. 10, pp. 9394-9414
Open Access | Times Cited: 13
Gamma oscillation modulation for cognitive impairment: A systematic review
Emanuela Bartolini, Adolfo Di Crosta, Pasquale La Malva, et al.
Journal of Alzheimer s Disease (2025)
Open Access
Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer’s pathologies?
Sushmitaa Dhevii Manoharan, Hafizah Abdul Hamid, Nur Fariesha Md Hashim, et al.
Brain Research (2024) Vol. 1829, pp. 148793-148793
Closed Access | Times Cited: 4
Tryptamine: A privileged scaffold for the management of Alzheimer's disease
Yash Pal Singh, Harish Kumar
Drug Development Research (2023) Vol. 84, Iss. 8, pp. 1578-1594
Closed Access | Times Cited: 10
A Comparative Study between Lycorine and Galantamine Abilities to Interact with AMYLOID β and Reduce In Vitro Neurotoxicity
Arian Kola, Stefania Lamponi, Francesco Currò, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2500-2500
Open Access | Times Cited: 9
Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment
Akash Verma, Digambar Kumar Waiker, Neha Singh, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116450-116450
Closed Access | Times Cited: 3
Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease
Prashanth Punyakoti, Tapan Behl, Aayush Sehgal, et al.
Cellular Signalling (2022) Vol. 102, pp. 110539-110539
Closed Access | Times Cited: 14
Getting ahead of Alzheimer’s disease: early intervention with focused ultrasound
Rebecca L. Noel, Samantha Gorman, Alec J. Batts, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 6
Berberine derivatives as inhibitors of acetylcholinesterase: A systematic review
Yash Pal Singh, Harish Kumar
Chemical Biology & Drug Design (2023) Vol. 102, Iss. 6, pp. 1592-1603
Closed Access | Times Cited: 5
The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review
Anum Rasheed, Ahmad Bin Zaheer, Aqsa Munawwar, et al.
Life (2022) Vol. 13, Iss. 1, pp. 1-1
Open Access | Times Cited: 8
Update on new trends and progress of natural active ingredients in the intervention of Alzheimer's disease, based on understanding of traditional Chinese and Western relevant theories: A review
Weipei Li, Yifeng Rang, Huan Liu, et al.
Phytotherapy Research (2023) Vol. 37, Iss. 9, pp. 3744-3764
Closed Access | Times Cited: 4
Dipeptidyl Peptidase 4 mediated Caspase-8 Affects Cognitive Impairment in Mice with Alzheimer's Disease
Xinyi Wang, Li Chen, Ke Wang, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Recent Molecular Targets and Their Ligands for the Treatment of Alzheimer Disease
Gülşah Bayraktar, Vildan Alptüzün
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 28, pp. 2447-2464
Closed Access | Times Cited: 1
PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE
Phool Chandra, Vikas Sharma
INDIAN DRUGS (2024) Vol. 61, Iss. 07, pp. 7-22
Closed Access | Times Cited: 1
Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents
Nguyễn Văn Mạnh, Van-Hai Hoang, Van T.H. Ngo, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114837-114837
Closed Access | Times Cited: 6
Synthesis and cholinesterases inhibitory effects of water soluble zinc(II) and silicon(IV) phthalocyanines bearing ({8‐[3‐(dimethylamino)phenoxy]octyl}oxy) groups
Berna Usta, Gökçe Seyhan, Didem Akkaya, et al.
Applied Organometallic Chemistry (2024) Vol. 38, Iss. 11
Open Access
Page 1 - Next Page

Scroll to top